Abivax Expands Trial for Potential Crohn’s Disease Treatment

Abivax SA (FR:ABVX) has released an update.

Abivax SA has commenced a phase 2b clinical trial, ENHANCE-CD, to evaluate the efficacy and tolerance of its experimental drug, obefazimod, in treating moderately to severely active Crohn’s disease. The trial aims to provide a new oral, once-daily treatment option for patients who have not responded well to existing therapies. Positive phase 2 data from ulcerative colitis trials have already led to a phase 3 program for obefazimod, underscoring its potential in treating inflammatory bowel diseases.

For further insights into FR:ABVX stock, check out TipRanks’ Stock Analysis page.